Risk Of Developing Liver Cancer After HCV Treatment

Wednesday, January 31, 2018

Clinical predictors of liver fibrosis in patients with chronic hepatitis B virus infection from children to adults

The Journal of Infectious Diseases, jiy048, https://doi.org/10.1093/infdis/jiy048

Accepted ManuscriptClinical predictors of liver fibrosis in patients with chronic hepatitis B virus infection from children to adults
Jia-Feng Wu Shih-Hsi Song Chee-Seng Lee Huey-Ling Chen Yen-Hsuan Ni Hong-Yuan Hsu Tzee-Chung Wu Mei-Hwei Chang

Published: 30 January 2018

Full Text
Download PDF

Abstract
Background
This study aimed to elucidate predictors of liver fibrosis in chronic hepatitis B virus (HBV)-infected subjects.

Methods
Transient elastography was performed to define liver fibrosis in 533 chronic HBV-infected patients at 30.72 ± 0.57 years of age. Protein array was performed on serum samples and lysates of Huh7 cells transfected with HBV mutants; the results were confirmed by ELISA. Single nucleotide polymorphisms in the interleukin-1β gene were examined chronic HBV-infected patients with and without liver fibrosis.

Results
Male gender, > 18 years old, and serum alpha-fetoprotein level > 3.6 ng/mL were independent predictors of a liver stiffness measurement of ≥ 7 kPa (P = 0.005, 0.019, and < 0.001, respectively). HBeAg-negative hepatitis is associated with increased liver stiffness (P<0.001). Elevation of serum interleukin-1β was demonstrated in subjects with liver fibrosis. Interleukin-1β was upregulated in Huh7 cells transfected with HBeAg-negative hepatitis-related mutants. The AA genotype at rs16944 and the CC genotype at rs1143627 of the interleukin-1β gene were associated with higher serum interleukin-1β levels and liver fibrosis.

Conclusions
Male gender, beyond childhood, elevated alpha-fetoprotein level, and HBeAg-negative hepatitis are risk factors for liver fibrosis. Interleukin-1β is involved in the progression of liver fibrosis in subjects with HBeAg-negative hepatitis.

No comments:

Post a Comment